Parkinson disease (PD) is an age-related neurodegenerative disorder that affects as many
as 1–2% of persons aged 60 years and older. With the aging of the population, the …

Abstract The Movement Disorder Society Task Force for Rating Scales for Parkinson's
Disease prepared a critique of the Unified Parkinson's Disease Rating Scale (UPDRS) …

Background Despite the known benefit of levodopa in reducing the symptoms of Parkinson's
disease, concern has been expressed that its use might hasten neurodegeneration. This …

Parkinsonism is a clinical syndrome comprising combinations of motor problems—namely,
bradykinesia, resting tremor, rigidity, flexed posture,“freezing,” and loss of postural reflexes …

Parkinson's disease (PD) is a neurodegenerative disorder that affects millions of people
worldwide. Two hallmarks of PD are the accumulation of alpha‐synuclein and the loss of …

Abstract In 1992 the Core Assessment Program for Intracerebral Transplantations (CAPIT)
was published providing the minimal requirements for a common patient evaluation …

Aggregation of α-synuclein (α-syn) is neuropathologically and genetically linked to
Parkinson's disease (PD). Since stereotypic cell-to-cell spreading of α-syn pathology is …

Molecular imaging is an attractive technology widely used in clinical practice that greatly
enhances our understanding of the pathophysiology and treatment in central nervous …

ContextPramipexole and levodopa are effective medications to treat motor symptoms of
early Parkinson disease (PD). In vitro and animal studies suggest that pramipexole may …

OBJECTIVES: The main neuropathological feature in Parkinson's disease is a severe
degeneration of the dopaminergic neurons in the substantia nigra resulting in a loss of …